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Background
In clinical practice, allergic rhinitis (AR) patients fre-
quently present with a predominant or particularly bother-
some symptom, most frequently nasal congestion.
Objective
To assess the efficacy of MP29-02* (a novel intranasal for-
mulation of azelastine hydrochloride [AZE] and flutica-
sone propionate [FP]) in patients with seasonal AR (SAR)
suffering predominantly from nasal congestion, compared
to commercially available AZE or FP nasal sprays and
placebo.
Methods
610 patients (≥12 years old) with moderate-to-severe SAR
were randomized into a double-blind, placebo-controlled,
14-day, parallel-group trial to MP29-02*, AZE or FP nasal
sprays and placebo (all given as 1 spray/nostril bid; total
daily dose: 548µg AZE, 200µg FP]. Patients were defined
as ‘nasal congestion predominants’ if their maximum
symptom score at baseline was the nasal congestion score
(n=368). Both reflective total nasal symptom score
(rTNSS; max score =24) and nasal congestion symptom
score (max score =6) reduction were assessed in these
patients to show effect on their overall nasal symptom
burden, as well as specific relief from nasal congestion.
Results
MP29-02* induced the greatest reduction in rTNSS in
patients complaining of nasal congestion (-5.64), compared
to -3.93 for FP (Diff -1.71; 95% CI -3.00, -0.43; p=0.0093),
-3.28 for AZE (Diff -2.36; 95% CI -3.51, -1.21; p<0.0001)
and -2.63 for placebo (Diff -3.01; 95% CI -4.14, -1.88;
p<0.0001), corresponding to a relative treatment difference
of 57% to FP and 79% to AZE. These nasal congestion-
predominant patients treated with MP29-02* also experi-
enced a significantly greater reduction in their nasal
congestion score; -1.41 vs -0.90 for FP (Diff: -0.51; 95% CI
-0.83, -0.19; p=0.0018), -0.83 for AZE (Diff: -0.58; 95% CI
-0.88, -0.29; p=0.0001) and -0.69 for placebo (Diff -0.72;
95% CI -1.02, -0.42; p<0.0001), with a relative treatment dif-
ference of 71% to FP and 81% to AZE. Neither AZE nor FP
significantly differed from placebo in terms of nasal conges-
tion reduction in these patients.
Conclusion
Unlike currently available first line therapy, MP29-02*
effectively reduced nasal congestion and the overall
nasal symptom burden of patients suffering predomi-
nantly from nasal congestion. This indicates that for
nasal congestion predominant patients a decongestant
might not be required prior to MP29-02* administra-
tion, and further supports the position of MP29-02*as
the drug of choice for the treatment of AR.
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